Less than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its inaugural advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a long-term condition that can be treated with thorough and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major barriers to widespread availability to the treatments that can aid individuals in losing significant body mass, notes the organization.
GLP-1 Therapy Shortage
Even in the present most optimistic case, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline encourages nations and manufacturers to expand access, by measures like voluntary licensing.
A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Jabs Function
These medications imitate a natural hormone to slow digestion, curb appetite and boost feelings of fullness so people consume fewer calories.
Patients usually see weight reduction in the initial weeks of beginning the once-weekly jabs.
Evidence suggests users may see weight return after a year of halting the drug, because their normal appetite resume.
Being carrying excess weight elevates your likelihood for developing medical conditions, like diabetes, heart disease, stroke, and certain cancers.
Obesity affects individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
